Non-invasive AI Leverage Vektor Medical’s FDA-cleared non-invasive vMap technology to target cardiology clinics and hospitals looking to improve accuracy and speed in arrhythmia localization, opening conversations around adoption in electrophysiology workflows.

Growth signal With a Series A financing of $16M and leadership expansion including a new CFO and VP of Sales, engage growth-stage health tech investors and enterprise buyers by highlighting scalable sales motions, channel partnerships, and expanding market penetration.

Clinical validation Position vMap as a differentiator in arrhythmia care by showcasing FDA clearance and CE marking, supporting outreach to hospitals and ambulatory centers seeking compliant, clinically validated solutions that can shorten procedure times.

Events and visibility Capitalize on appearances at Heart Rhythm events and San Diego-based positioning by coordinating targeted demonstrations, physician evangelists, and CME-style education sessions to drive trials and adoption among electrophysiologists.

Revenue potential Target mid-market to large clinics with growing arrhythmia programs, offering scalable pricing, implementation support, and outcomes-based value propositions to convert interest into multi-site deployments and recurring revenue.